Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2016

View Archived Issues

Renaissance topical division sold to Mylan

Kyushu University and Nippon Chemiphar begin phase I trial for NC-2600

MTD for PQR-309 determined in patients with advanced solid tumors

Phase II results for TRC-105 plus bevacizumab in patients with bevacizumab-refractory glioblastoma

Phase II results for CDX-1401 in patients with malignant melanoma pretreated with CDX-301

Boehringer Ingelheim discloses aldosterone synthase inhibitors

The Meghan Rose Bradley Foundation supports VBI Vaccines' immunotherapy research

Delta-Fly Pharma patents drug conjugates to treat cancer

C&C Research Laboratories announces STAT3 inhibitors

Actelion Pharmaceuticals divulges chemokine receptor agonists

Cerus enters into agreement with BARDA for INTERCEPT funding

Grunenthal reports TRPV1 ligands

The Medicines Co. presents new beta-lactamase inhibitors

Poxel advances phase I trial of direct AMPK activator PXL-770

Orbus Therapeutics' brain cancer drug receives EMA orphan medicinal product status

GSK's FULFIL study of closed triple combination therapy for COPD meets co-primary endpoints

TiGenix reports phase I/II results on AlloCSC-01

Orphazyme begins dosing patients in phase III AIDNPC interventional study

Circassia's phase III cat allergy study fails to meet primary endpoint

Japan Tobacco receives Japanese manufacturing and marketing approval for Genvoya

ARIAD Pharmaceuticals begins rolling NDA submission for brigatinib

Safety and pharmacokinetics of anti-IL-17 MAb assessed in phase I study

Phase II expansion investigates savolitinib with osimertinib for advanced EGFR-mutant NSCLC

MEDI-3902 combined with tobramycin shows promise in an acute pneumonia model

Summit Therapeutics enrolls first patient in Phaseout DMD study

FDA grants EUA to Hologic's Aptima Zika Virus assay

Roche's LightMix Modular Zika Virus Assay now available

Blade Therapeutics closes series B financing

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...